9999999997-16-023605.txt : 20160609 9999999997-16-023605.hdr.sgml : 20160609 20160609171804 ACCESSION NUMBER: 9999999997-16-023605 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20160609 DATE AS OF CHANGE: 20160609 20160609 20160609 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOCRYST PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000882796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 621413174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 000-23186 FILM NUMBER: 161706739 BUSINESS ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-859-1302 MAIL ADDRESS: STREET 1: 4505 EMPEROR BOULEVARD STREET 2: SUITE 200 CITY: DURHAM STATE: NC ZIP: 27703 CT ORDER 1 filename1.pdf begin 644 filename1.pdf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